New York State Common Retirement Fund Has $25.79 Million Stake in Grifols, S.A. $GRFS

New York State Common Retirement Fund raised its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 5.6% in the 3rd quarter, Holdings Channel reports. The firm owned 2,589,406 shares of the biotechnology company’s stock after purchasing an additional 136,678 shares during the quarter. New York State Common Retirement Fund’s holdings in Grifols were worth $25,790,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc increased its stake in shares of Grifols by 39.5% in the third quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 1,584 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Grifols by 127.4% in the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 4,604 shares during the period. Ameriprise Financial Inc. bought a new stake in Grifols in the second quarter valued at approximately $95,000. R Squared Ltd bought a new stake in Grifols in the second quarter valued at approximately $95,000. Finally, Bessemer Group Inc. increased its position in Grifols by 1,693.8% during the 2nd quarter. Bessemer Group Inc. now owns 11,821 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 11,162 shares during the period.

Analysts Set New Price Targets

GRFS has been the topic of a number of recent analyst reports. Zacks Research downgraded shares of Grifols from a “hold” rating to a “strong sell” rating in a research report on Friday, December 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Grifols in a research note on Thursday, January 22nd. JPMorgan Chase & Co. dropped their target price on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a report on Monday, December 8th. Finally, Wall Street Zen upgraded Grifols from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Grifols currently has an average rating of “Hold” and an average price target of $10.00.

Grifols Trading Down 0.4%

NASDAQ:GRFS opened at $9.25 on Friday. Grifols, S.A. has a 12 month low of $6.19 and a 12 month high of $11.14. The company has a current ratio of 2.48, a quick ratio of 0.93 and a debt-to-equity ratio of 1.20. The stock has a market capitalization of $6.39 billion, a price-to-earnings ratio of 48.68, a PEG ratio of 0.32 and a beta of 0.67. The firm has a fifty day simple moving average of $9.04 and a two-hundred day simple moving average of $9.49.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.